Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era

被引：12

作者：

Wang, Shaoli ^{[1
]}

Chen, Siying ^{[1
]}

Zhong, Qionglei ^{[1
]}

Liu, Yan ^{[2
]}

机构：

[1] Hainan Med Univ, Hainan Gen Hosp, Otolaryngol Dept, Hainan Affiliated Hosp, Xiuhua Rd, Haikou, Hainan, Peoples R China

[2] Dalian Med Univ, Otolaryngol Dept, Affiliated Hosp 1, 222 Zhongshan Rd, Dalian, Liaoning, Peoples R China

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023年 / 149卷 / 05期

关键词：

R; M NPC; Immunotherapy; PD-1; CTLA-4; EBV; ANTITUMOR-ACTIVITY; 1ST-LINE TREATMENT; RECURRENT; CHEMOTHERAPY; SAFETY; PEMBROLIZUMAB; RADIOTHERAPY; COMBINATION; MULTICENTER; THERAPY;

D O I：

10.1007/s00432-022-04214-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Nasopharyngeal carcinoma (NPC) is ranked the top otorhinolaryngology malignant tumors in the world. However, the general prognosis of recurrent and metastatic (R/M) nasopharyngeal carcinomas (NPCs) remains poor, and current surgery and chemoradiotherapy do not generate satisfactory outcomes. Methods As a new therapeutic choice, immunotherapy, especially with regard to the development of checkpoint inhibitors including PD-1 and CTLA-4 inhibitors have made considerable progress in recent years. As Epstein-Barr virus (EBV) infection is associated with increased risk of NPC, EBV-related immunotherapy may lead to a breakthrough in advanced NPCs. Results In this review, we summarized the clinical characters of NPC, and several past and ongoing clinical trials of checkpoint inhibitors and EBV-CTLs (CTLs: cytotoxic T lymphocytes) in R/M NPC immunotherapy. Conclusion We conclude that although the evaluated effects of new immunotherapy drugs have brought us hope on NPC treatment, further phase II-III trials with larger samples are still required to improve the proportion and scheme of drug collocation for better clinical outcomes and less drug-related safety.

引用

页码：2071 / 2079

页数：9